KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Thermo Fisher Scientific (TMO) EBT Margin (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of EBT Margin readings, the most recent being 15.76% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 13.0% to 15.76% in Q1 2026 year-over-year; TTM through Mar 2026 was 16.42%, a 5.0% decrease, with the full-year FY2025 number at 16.4%, down 1.0% from a year prior.
  • EBT Margin hit 15.76% in Q1 2026 for Thermo Fisher Scientific, down from 17.63% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 21.49% in Q2 2022 to a low of 12.73% in Q2 2023.
  • Median EBT Margin over the past 5 years was 15.98% (2023), compared with a mean of 16.18%.
  • Biggest five-year swings in EBT Margin: plummeted -877bps in 2023 and later surged 336bps in 2024.
  • Thermo Fisher Scientific's EBT Margin stood at 15.52% in 2022, then grew by 3bps to 15.98% in 2023, then rose by 7bps to 17.03% in 2024, then increased by 3bps to 17.63% in 2025, then dropped by -11bps to 15.76% in 2026.
  • The last three reported values for EBT Margin were 15.76% (Q1 2026), 17.63% (Q4 2025), and 16.42% (Q3 2025) per Business Quant data.